Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Site-selective modification strategies in antibody–drug conjugates
Stephen J. Walsh, Jonathan D. Bargh, Friederike M. Dannheim, et al.
Chemical Society Reviews (2020) Vol. 50, Iss. 2, pp. 1305-1353
Open Access | Times Cited: 312

Showing 1-25 of 312 citing articles:

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 911
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Juliana T. W. Tong, Paul W. R. Harris, Margaret A. Brimble, et al.
Molecules (2021) Vol. 26, Iss. 19, pp. 5847-5847
Open Access | Times Cited: 235
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Toan D. Nguyen, Brandon M. Bordeau, Joseph P. Balthasar
Cancers (2023) Vol. 15, Iss. 3, pp. 713-713
Open Access | Times Cited: 154
Targeting cancer with antibody-drug conjugates: Promises and challenges
Alexis Q. Dean, Shen Luo, Julianne D. Twomey, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 144
Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 141
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2534-2575
Closed Access | Times Cited: 118
Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 85
A comprehensive review of key factors affecting the efficacy of antibody drug conjugate
Anupama Samantasinghar, Naina Sunildutt, Faheem Ahmed, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114408-114408
Open Access | Times Cited: 69
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
Exploration of the antibody–drug conjugate clinical landscape
Heather Maecker, Vidya S. Jonnalagadda, Sunil Bhakta, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 60
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 36
Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates
Murugaiah A. M. Subbaiah, Jarkko Rautio, Nicholas A. Meanwell
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 2099-2210
Closed Access | Times Cited: 27
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 19
Selenium chemistry for spatio-selective peptide and protein functionalization
Zhenguang Zhao, Shay Laps, Jacob S. Gichtin, et al.
Nature Reviews Chemistry (2024) Vol. 8, Iss. 3, pp. 211-229
Closed Access | Times Cited: 18
Trastuzumab deruxtecan in breast cancer
Miguel Martín, Atanasio Pandiella, Emilio Vargas, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104355-104355
Open Access | Times Cited: 17
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 16
Targeting antibodies dissociate from drug delivery liposomes during blood circulation
Unnur Jóna Björgvinsdóttir, Jannik B. Larsen, Martin Bak, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 982-992
Open Access | Times Cited: 2
The Chemistry Behind ADCs
Vesela Kostova, Patrice Désos, Jérôme-Benoît Starck, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 5, pp. 442-442
Open Access | Times Cited: 83
Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates
Min Sun Kang, Theresa Wai See Kong, Yi Xin Joycelyn Khoo, et al.
Chemical Science (2021) Vol. 12, Iss. 41, pp. 13613-13647
Open Access | Times Cited: 83
Antibody-based cancer therapy
Rebecca S. Goydel, Christoph Rader
Oncogene (2021) Vol. 40, Iss. 21, pp. 3655-3664
Open Access | Times Cited: 68
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Yurou Chu, Xiangxiang Zhou, Xin Wang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 59
Peptide-Drug Conjugates: A New Hope for Cancer Management
Vivek P. Chavda, Hetvi K. Solanki, Majid Davidson, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7232-7232
Open Access | Times Cited: 59
Degrader–Antibody Conjugates: Emerging New Modality
Ki Bum Hong, Hongchan An
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 140-148
Closed Access | Times Cited: 44
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production
Tomohiro Fujii, Yutaka Matsuda, Takuya Seki, et al.
Bioconjugate Chemistry (2023)
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top